Peer-influenced content. Sources you trust. No registration required. This is HCN.
The approval of capmatinib and its companion diagnostic is the first of its kind for this specific diagnosis, using next-generation sequencing to perform comprehensive genomic profiling of solid tumors. It now has FDA approval for 21 different agents.
Hematology June 29th 2020
According to the results of a single-arm, multicenter phase 2 trial in JAMA Oncology, low-dose erlotinib may be a safe and effective option for frail or elderly patients with EGFR mutation-positive NSCLC.
Geriatrics June 29th 2020
Based on monotherapy data from an open-label, multi-center, single-arm study of 105 adults with platinum-sensitive and platinum-resistant SCLC that progressed after platinum-based chemotherapy, the FDA granted accelerated approval to lurbinectedin (Zepzelca; Jazz Pharmaceuticals and PharmaMar).
Hematology June 22nd 2020
Published in Practical Radiation Oncology, the recommendations from the American Society for Radiation Oncology (ASTRO) are based on a systematic literature review, consensus, and system for grading evidence quality and recommendation strength.
Healthgrades for Professionals
As a result of COVID-19, many physicians had to provide telemedicine services in a matter of weeks, if not days. A major accomplishment, for sure. But are you getting paid for your hard work? Read on to find out how you can ensure you are being compensated for the work you’ve been doing.
Allergy & Immunology June 22nd 2020
Based on the data from the ATTRACTION-3 clinical trial, the FDA approved nivolumab (Opdivo; BMS) for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) who previously received fluoropyrimidine- and platinum-based chemotherapy.
Gastroenterology June 15th 2020